Nurix Therapeutics, Inc. (NRIX) P/S ratio

P/S ratio today
14.7×

Nurix Therapeutics, Inc. (NRIX) trades at 14.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (November 30, 2025) its P/S ratio was 18.2×. That is 32.9% lower than the 27.2× of fiscal 2024. Figures as of 18 Nov 2026, 09:32 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
14.7×
P/S ratio, fiscal 2025
18.2×
Change on fiscal 2024
−32.9%
Highest on record
41.6×fiscal 2021
Lowest on record
4.4×fiscal 2023
Fiscal years on record
52021–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Nurix Therapeutics, Inc. P/S ratio, in more detail

Today's figure is 19.5% below the fiscal 2025 year-end.

Across the 5 fiscal year-ends on record (2021–2025), the highest was 41.6× in fiscal 2021 and the lowest 4.4× in fiscal 2023. Today's P/S ratio is higher than at 20% of the 5 fiscal year-ends on record; their median is 18.2×.

History · 5 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Nurix Therapeutics, Inc. P/S ratio, year by year

Nurix Therapeutics, Inc. (NRIX) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today14.7×—$14.24—
202518.2× 32.9% down$17.68$0.97
202427.2× 519.7% up$22.11$0.81
20234.4× 71.8% down$6.22$1.42
202215.6× 62.5% down$12.39$0.79
202141.6×—$28.82$0.69
2020——$42.62—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on NRIX

Nurix Therapeutics, Inc., figure by figure

Nurix Therapeutics, Inc. (NRIX) overview: price, valuation and scorecard

Nurix Therapeutics, Inc. P/S ratio: questions and answers

What is Nurix Therapeutics, Inc.'s P/S ratio?

Nurix Therapeutics, Inc. (NRIX) trades at 14.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (November 30, 2025) its P/S ratio was 18.2×. That is 32.9% lower than the 27.2× of fiscal 2024.

Is Nurix Therapeutics, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 20% of the 5 fiscal year-ends on record; their median is 18.2×.

What are the highest and lowest P/S ratio figures on record for Nurix Therapeutics, Inc.?

Across the 5 fiscal year-ends on record (2021–2025), the highest was 41.6× in fiscal 2021 and the lowest 4.4× in fiscal 2023.

How is Nurix Therapeutics, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Nurix Therapeutics, Inc. it is on record here for 5 fiscal years, 2021 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Nurix Therapeutics, Inc. (NRIX) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/NRIX/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.